Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada.

MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium presentation details:

Poster Title:Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial
Presenter:Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences
Session:Poster Session 1; Vancouver Island Room
Date/Time:Monday, April 13, 2026, at 7:30 PM PT
Location:Fairmont Hotel, Vancouver, BC, Canada
Presentation Title:Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial
Presenter:Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences
Session:Symposia Spotlight 2: Inflammation and Fibrosis in the Obese Liver, Columbia Ballroom
Date/Time:Wednesday, April 15, 2026, at 2:30-4:30 PM PT
Location:Fairmont Hotel, Vancouver, BC, Canada

Poster and Presentation Highlights:

Elevated serum bile acid levels have been associated with metabolic disorders such as MASH and type 2 diabetes. In Sagimet's Phase 2b FASCINATE-2 clinical trial, denifanstat-treated MASH patients who were histological responders for both fibrosis regression and MASH resolution showed significant reduction in glycine- and taurine-conjugated bile acids at 26 weeks. These data suggest that these circulating bile acid levels may potentially be leveraged as a response biomarker in patients treated with denifanstat.

Inducement Grant

In connection with the hiring of an employee, the Compensation Committee of Sagimet's Board of Directors approved that an inducement grant of 9,600 stock options to purchase shares of the Company's Series A common stock, be granted on April 3, 2026, to the newly hired employee.

The option award was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of the individual's employment compensation and was granted as an inducement material to the acceptance of employment with Sagimet.

The options have an exercise price equal to the closing price of Sagimet's Series A common stock as reported by the Nasdaq Global Market on April 2, 2026. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying each stock option vesting on the one-year anniversary of the applicable vesting commencement date (based on the employee's employment commencement date) and the remaining shares vesting monthly over 36 months thereafter, subject to the individual's continued service with Sagimet through the applicable vesting dates.